EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Growth factor supportive care for chemotherapy-induced neutropenia suppresses antitumour immunity in checkpoint blockade-responsive pancreatic cancer

Brendan D Parent iD, Anthony E Kelly, Megan T Hoffman, Michael Dougan, Andrew J Aguirre, Stephanie K Dougan iD

Immunotherapy Advances · 31.12.2025 · 6 (1)

DOI: 10.1093/immadv/ltag013 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Immunotherapy Advances, online erschienen am 15.07.2026. Verfasst von Brendan D Parent und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA. Die Arbeit nennt 38 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NCI NIH HHS, NIAID NIH HHS, Hale Center for Pancreatic Cancer Research.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

Growth factors, including granulocyte colony-stimulating factor (G-CSF; pegfilgrastim, filgrastim), are used for prophylaxis or treatment of chemotherapy-induced neutropenia, yet their effects on antitumour immunity remain incompletely understood. We previously found that serum from patients with pancreatic ductal adenocarcinoma (PDAC) treated with multiagent chemotherapy plus G-CSF drove differentiation of T cell-suppressive monocytes in vitro, suggesting that supportive care interventions may shape immune responses in this disease.

Methods

We evaluated the immunologic and therapeutic impact of G-CSF in two murine PDAC models that differ in their baseline frequencies of infiltrating T cells and in their responsiveness to checkpoint blockade immunotherapy.

Results

In poorly immunogenic, T-cell-low tumours, use of G-CSF did not affect tumour growth or response to chemo- or immunotherapy, although neutrophil recovery was improved in mice receiving FOLFIRINOX and G-CSF compared to chemotherapy alone. In immunogenic tumours with a robust endogenous T-cell response, combination anti-PD1 and anti-CTLA-4 therapy resulted in durable tumour clearance. Combination with G-CSF diminished the effectiveness of checkpoint blockade and resulted in significantly fewer cured mice.

Conclusion

G-CSF, commonly used for supportive care with FOLFIRINOX and other chemotherapy regimens, induces systemic immune suppression that can reduce the efficacy of T-cell-targeting immunotherapies.

Schlagwörter

Stichwörter der Autor:innen

G-CSFcheckpoint blockadefilgrastimneutrophilspancreatic cancerpegfilgrastim

Autor:innen und Institutionen

  • Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
  • Amherst College, Amherst, MA, USA.
  • Department of Cancer Immunology and Virology, Dana-Farber Cancer Institute, Boston, MA, USA.
  • Department of Immunology, Harvard Medical School, 350 Longwood Ave, Boston, MA 02115, USA.
  • Department of Medicine, Division of Gastroenterology, Massachusetts General Hospital, Boston, MA, USA.
  • Department of Medicine, Harvard Medical School, Boston, MA, USA.

ORCID-Profile: Brendan D Parent, Stephanie K Dougan

Förderung

  • NCI NIH HHS
  • NIAID NIH HHS
  • Hale Center for Pancreatic Cancer Research
  • Break Through Cancer
  • Ludwig Center at Harvard
  • National Institutes of Health
  • Parker Institute for Cancer Immunotherapy
  • Peter and Ann Lambertus Family Foundation

Zitieren

APA

Parent, B. D., Kelly, A. E., Hoffman, M. T., Dougan, M., Aguirre, A. J., & Dougan, S. K. (2025). Growth factor supportive care for chemotherapy-induced neutropenia suppresses antitumour immunity in checkpoint blockade-responsive pancreatic cancer. Immunotherapy Advances, 6(1). https://doi.org/10.1093/immadv/ltag013

Vancouver

Parent BD, Kelly AE, Hoffman MT, Dougan M, Aguirre AJ, Dougan SK. Growth factor supportive care for chemotherapy-induced neutropenia suppresses antitumour immunity in checkpoint blockade-responsive pancreatic cancer. Immunotherapy Advances. 2025;6(1). doi:10.1093/immadv/ltag013

BibTeX
@article{Parent2025,
  author = {Parent, Brendan D and Kelly, Anthony E and Hoffman, Megan T and Dougan, Michael and Aguirre, Andrew J and Dougan, Stephanie K},
  title = {Growth factor supportive care for chemotherapy-induced neutropenia suppresses antitumour immunity in checkpoint blockade-responsive pancreatic cancer},
  journal = {Immunotherapy Advances},
  year = {2025},
  volume = {6},
  number = {1},
  doi = {10.1093/immadv/ltag013}
}
Kostenlos starten →